These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 24137579)
1. An evaluation of the predictive value of mid-treatment 18F-FDG-PET/CT scans in pediatric lymphomas and undefined criteria of abnormality in quantitative analysis. Zhu HJ; Halkar R; Alavi A; Goris ML Hell J Nucl Med; 2013; 16(3):169-74. PubMed ID: 24137579 [TBL] [Abstract][Full Text] [Related]
2. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment. Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734 [TBL] [Abstract][Full Text] [Related]
3. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer. Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010 [TBL] [Abstract][Full Text] [Related]
4. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma. Qiu L; Chen Y; Wu J Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577 [TBL] [Abstract][Full Text] [Related]
5. Risk factors for N2 metastasis in patients with non-small-cell lung cancer: multivariate analyses of 18F-FDG PET/CT data. Su M; Li Y; Li F; Li L; Tian R Nucl Med Commun; 2014 Sep; 35(9):916-21. PubMed ID: 24785010 [TBL] [Abstract][Full Text] [Related]
6. FDG PET-CT in the management of primary breast lymphoma. Santra A; Kumar R; Reddy R; Halanaik D; Kumar R; Bal CS; Malhotra A Clin Nucl Med; 2009 Dec; 34(12):848-53. PubMed ID: 20139815 [TBL] [Abstract][Full Text] [Related]
7. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis. Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032 [TBL] [Abstract][Full Text] [Related]
8. Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy? Koolen BB; Elshof LE; Loo CE; Wesseling J; Vrancken Peeters MJ; Vogel WV; Rutgers EJ; Valdés Olmos RA Eur J Radiol; 2013 Dec; 82(12):2353-8. PubMed ID: 23998705 [TBL] [Abstract][Full Text] [Related]
9. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center. Khong PL; Huang B; Lee EY; Chan WK; Kwong YL J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420 [TBL] [Abstract][Full Text] [Related]
10. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas]. Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637 [TBL] [Abstract][Full Text] [Related]
11. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT. Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871 [TBL] [Abstract][Full Text] [Related]
12. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence. Metser U; Miller E; Lerman H; Even-Sapir E AJR Am J Roentgenol; 2007 Nov; 189(5):1203-10. PubMed ID: 17954662 [TBL] [Abstract][Full Text] [Related]
13. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. Kasamon YL; Jones RJ; Wahl RL J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717 [TBL] [Abstract][Full Text] [Related]
14. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases]. Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458 [TBL] [Abstract][Full Text] [Related]
15. Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer. Chung HH; Kim JW; Kang KW; Park NH; Song YS; Chung JK; Kang SB Eur J Radiol; 2012 Aug; 81(8):e817-22. PubMed ID: 22595504 [TBL] [Abstract][Full Text] [Related]
16. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma. Graafland NM; Leijte JA; Valdés Olmos RA; Hoefnagel CA; Teertstra HJ; Horenblas S Eur Urol; 2009 Aug; 56(2):339-45. PubMed ID: 19477581 [TBL] [Abstract][Full Text] [Related]
17. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. Jacene HA; Leboulleux S; Baba S; Chatzifotiadis D; Goudarzi B; Teytelbaum O; Horton KM; Kamel I; Macura KJ; Tsai HL; Kowalski J; Wahl RL J Nucl Med; 2009 Nov; 50(11):1760-9. PubMed ID: 19837757 [TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046 [TBL] [Abstract][Full Text] [Related]
19. Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary. Wang G; Wu Y; Zhang W; Li J; Wu P; Xie C J Med Imaging Radiat Oncol; 2013 Feb; 57(1):65-71. PubMed ID: 23374557 [TBL] [Abstract][Full Text] [Related]
20. Thyroid incidentalomas on FDG PET/CT in patients with non-thyroid cancer - a large retrospective monocentric study. Kim H; Kim SJ; Kim IJ; Kim K Onkologie; 2013; 36(5):260-4. PubMed ID: 23689220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]